Skip to main content
Premium Trial:

Request an Annual Quote

Serologicals Reports Q1 Revenue Decline as R&D Spending Surges and Profit Nearly Doubles

NEW YORK, April 26 (GenomeWeb News) - Serologicals today reported that first-quarter revenues slipped 2.8 percent as R&D spending jumped 11 percent and profits nearly doubled.


Total receipts for the three months ended April 2 fell to $55 million from $56.6 million in the year-ago period.


R&D spending increased to $5 million from $4.5 million.


Profits swell to $2.8 million, or $.08 per basic share, from $1.9 million, or $.06 per basic share year over year.


Serologicals said it had around $43 million in cash and equivalents as of April 2.


As GenomeWeb News reported yesterday, the company said it will be acquired by Millipore for $1.4 billion in cash.

The Scan

For Better Odds

Bloomberg reports that a child has been born following polygenic risk score screening as an embryo.

Booster Decision Expected

The New York Times reports the US Food and Drug Administration is expected to authorize a booster dose of the Pfizer-BioNTech SARS-CoV-2 vaccine this week for individuals over 65 or at high risk.

Snipping HIV Out

The Philadelphia Inquirer reports Temple University researchers are to test a gene-editing approach for treating HIV.

PLOS Papers on Cancer Risk Scores, Typhoid Fever in Colombia, Streptococcus Protection

In PLOS this week: application of cancer polygenic risk scores across ancestries, genetic diversity of typhoid fever-causing Salmonella, and more.